Alnylam Pharmaceuticals | ALNY - Current Liabilities

Stock Price
351.80
Daily Change
12.69 3.74%
Monthly
-11.57%
Yearly
29.82%
Q1 Forecast
327.65

Alnylam Pharmaceuticals reported $1.56B in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 356.58M 26.56M Sep/2025
Agios Pharmaceuticals USD 74.76M 4.35M Sep/2025
Alnylam Pharmaceuticals USD 1.56B 254.63M Sep/2025
Amgen USD 21.79B 1.32B Sep/2025
Arrowhead Research USD 195.49M 957K Sep/2025
BioMarin Pharmaceutical USD 798.44M 114.19M Sep/2025
Incyte USD 1.34B 60.11M Sep/2025
Ionis Pharmaceuticals USD 903.46M 6.22M Sep/2025
Moderna USD 1.68B 109M Sep/2025
Neurocrine Biosciences USD 638M 91.7M Sep/2025
Novartis USD 32B 286M Sep/2025
PTC Therapeutics USD 866.24M 238.44M Sep/2025
Regeneron Pharmaceuticals USD 4.43B 758.1M Sep/2025
Sanofi EUR 28.35B 9.32B Dec/2025
Sarepta Therapeutics USD 921.42M 1.48M Sep/2025
Takeda JPY 2.61T 470.53B Dec/2025
Tectonic Therapeutic USD 9.37M 1.99M Sep/2025
Ultragenyx Pharmaceutical USD 340.02M 46.78M Sep/2025
Vertex Pharmaceuticals USD 4.48B 336.9M Sep/2025
Xencor USD 86.48M 9.6M Sep/2025